The gastrointestinal tract is a major target organ in Acquired Immunodeficiency Syndrome (AIDS). Patients with AIDS frequently present with diarrhea and weight loss sometimes unassociated with the presence of an infectious agent. The secretory nature of the diarrhea and other characteristics suggest that the HIV virus may interact with a receptor on mucosal cells, a receptor which recognizes the secretory peptide VIP, and which results in the generation of second messengers responsible for electrolyte secretion. Because the virus or other sequela of the disease may lead to the release of other peptide hormones, which induce intestinal secretion (namely, gastric inhibitory peptide, calcitonin, neurotensin, and bombesin), we propose to study the profile of these peptides prior to and during the course of diarrhea in AIDS or ARC patients. Having a better understanding of which peptide(s) is(are) elevated during a particular phase of the disease, will aid in our development of better and more specific therapy for this debilitating symptom.
A second aim of the present proposal is to study the effects of a synthetic somatostatin analog, SMS 201-995, in AIDS patients with diarrhea. This substance has been demonstrated to be effective against VIP- induced diarrhea in man. We believe that it is likely that this compound will inhibit the diarrhea in AIDS, regardless of whether it is of infective origin or is due to elevated levels of VIP or related hormones. Furthermore, because of similarities between the HIV protein coat and the amino acid sequence in VIP, we anticipate that SMS 201-995 will be effective therapy in patients found to have diarrhea of undocumented (HIV?) etiology. In summary, this project will provide important information as to which, if any, of the secretory peptide hormones are elevated in AIDS and whether or not intervention therapy with SMS 201-955, will be of benefit in preventing the diarrhea due to a particular peptide, opportunistic infections of the GI tract, or due to the action of HIV virus on the epithelium.

Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Brashers, Dale E; Basinger, Erin D; Rintamaki, Lance S et al. (2017) Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV. Health Commun 32:11-21
Peterson, Jennifer L; Rintamaki, Lance S; Brashers, Dale E et al. (2012) The forms and functions of peer social support for people living with HIV. J Assoc Nurses AIDS Care 23:294-305
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Raboud, Janet M; Diong, Christina; Carr, Andrew et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39-50
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sax, Paul E; Tierney, Camlin; Collier, Ann C et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361:2230-40
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Collier, Ann C; Tierney, Camlin; Downey, Gerald F et al. (2008) Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials 9:91-102
Demeter, Lisa M; DeGruttola, Victor; Lustgarten, Stephanie et al. (2008) Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 9:11-25

Showing the most recent 10 out of 97 publications